On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
Zacks.com on MSN13d
FTC Report Reveals PBM Practices Impacting Competition and Drug CostsThe FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
Newsweek on MSN12d
UnitedHealth Charged Cancer Patients 5000%, Bombshell FTC Report ClaimsThe FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
Pharmacy Benefit Managers (PBM) sit in the center of our prescription drug system, coordinating between insurance companies, ...
Finally, blaming the pharmaceutical industry for high drug costs has historically been PBMs’ go-to defense. In a rebuttal to the FTC report issued in the summer, the PCMA criticized the ...
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback